{"id":384904,"date":"2020-11-19T08:03:21","date_gmt":"2020-11-19T13:03:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384904"},"modified":"2020-11-19T08:03:21","modified_gmt":"2020-11-19T13:03:21","slug":"aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","title":{"rendered":"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.<\/p>\n<p align=\"left\">The pre-recorded fireside chat will be accessible for a limited time beginning November 23, 2020 in the Investors section of Aprea Therapeutics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s6yXdEM_qQAN0EC__wMA5NEnIEpeYRmFUQNjylhbzMyhiD0W97CywzzjGyY4PplgqNP_HJqIpBsCQnukpvoRrQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.aprea.com<\/a>.<\/p>\n<p>\n        <strong>About\u00a0A<\/strong><br \/>\n        <strong>prea<\/strong><br \/>\n        <strong> Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Aprea Therapeutics, Inc.\u00a0is a biopharmaceutical company headquartered in\u00a0Boston, Massachusetts\u00a0with research facilities in\u00a0Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate\u00a0mutant tumor suppressor protein, p53. The Company\u2019s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s6yXdEM_qQAN0EC__wMA5BoU9qpg0xwWAnwf1Vc9AvW1jWwsROGPnQOnVLo0Nbth7jtNp0WkqCbDYsM6bbp3Yw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.aprea.com<\/a>.<\/p>\n<p>The Company may use, and intends to use, its investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z7stKP8sCvGXVlzmMKiH6kaIOkHm58GvgxLZ_fxuV_98B9TMrBcsrerytV2xZKS22qQVDvqP4iVGW9Jo-S-HJg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ir.aprea.com\/<\/a> as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.<\/p>\n<p>\n        <strong>Forward-Looking Statement<\/strong><br \/>\n        <br \/>Certain information contained in this press release includes \u201cforward-looking statements\u201d, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201ctargeting,\u201d \u201cconfidence,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the\u00a0U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.<\/p>\n<p>Source: Aprea Therapeutics, Inc.<\/p>\n<p>Corporate Contacts:<\/p>\n<p>Scott M. Coiante<br \/>Sr. Vice President and Chief Financial Officer<br \/>617-463-9385<\/p>\n<p>Gregory A. Korbel<br \/>Vice President of Business Development<br \/>617-463-9385<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f243af7c-0f41-4e9e-9895-88cafba9940b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. The pre-recorded fireside chat will be accessible for a limited time beginning November 23, 2020 in the Investors section of Aprea Therapeutics\u2019 website at www.aprea.com. About\u00a0A prea Therapeutics, Inc. Aprea Therapeutics, Inc.\u00a0is a biopharmaceutical company headquartered in\u00a0Boston, Massachusetts\u00a0with research facilities in\u00a0Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate\u00a0mutant tumor suppressor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384904","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. The pre-recorded fireside chat will be accessible for a limited time beginning November 23, 2020 in the Investors section of Aprea Therapeutics\u2019 website at www.aprea.com. About\u00a0A prea Therapeutics, Inc. Aprea Therapeutics, Inc.\u00a0is a biopharmaceutical company headquartered in\u00a0Boston, Massachusetts\u00a0with research facilities in\u00a0Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate\u00a0mutant tumor suppressor &hellip; Continue reading &quot;Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T13:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference\",\"datePublished\":\"2020-11-19T13:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"},\"wordCount\":539,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\",\"name\":\"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=\",\"datePublished\":\"2020-11-19T13:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","og_description":"BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. The pre-recorded fireside chat will be accessible for a limited time beginning November 23, 2020 in the Investors section of Aprea Therapeutics\u2019 website at www.aprea.com. About\u00a0A prea Therapeutics, Inc. Aprea Therapeutics, Inc.\u00a0is a biopharmaceutical company headquartered in\u00a0Boston, Massachusetts\u00a0with research facilities in\u00a0Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate\u00a0mutant tumor suppressor &hellip; Continue reading \"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T13:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference","datePublished":"2020-11-19T13:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/"},"wordCount":539,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/","name":"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=","datePublished":"2020-11-19T13:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODgyOCMzODM0NTk4IzIxODEyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384904"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384904\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}